Business Wire

Medicago Begins Phase I Clinical Trials for its COVID-19 Vaccine Candidate

Share

Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers. Medicago is also planning a Phase 2/3 trial to be initiated this October.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005585/en/

Vial of a vaccine candidate. (Photo: Business Wire)

Vial of a vaccine candidate. (Photo: Business Wire)

“We are thrilled to see our COVID-19 vaccine candidate enter the Phase 1 trial, and we look forward to obtaining safety and immunogenicity results in October,” said Nathalie Landry, Executive Vice-President, Scientific and Medical Affairs at Medicago. “Our progress continues to demonstrate the value of Medicago’s unique plant-based vaccine technology.”

The Phase I clinical trial is a randomized, partially blinded study of 180 normal healthy subjects, male and female aged 18-55, and will evaluate dosages of 3.75, 7.5 or 15 micrograms of the recombinant Coronavirus Virus-Like Particle (CoVLP) vaccine candidate alone or with an adjuvant in a prime-boost regimen. Medicago will be testing its vaccine candidate with two adjuvants separately – GSK’s proprietary pandemic adjuvant technology and Dynavax’s CpG 1018™. An adjuvant can be of particular importance in a pandemic situation as it may boost the immune response and reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and therefore contributing to protect the greatest number of people.

Medicago’s innovative platform and plant-based manufacturing technology is helping to diversify the pool of COVID-19 vaccines in development.

“Creating a sufficient supply of COVID-19 vaccines within the next year is a challenge which will require multiple approaches, with different technologies,” said Dr. Bruce Clark, President and CEO of Medicago. “Our proven plant-based technology is capable of contributing to the collective solution to this public health emergency.”

Medicago expects to be able to manufacture approximately 100 million doses by the end of 2021. By the end of 2023, the construction of Medicago’s large-scale facility in Quebec City, Canada, will be completed. It is anticipated that this commercial facility will have the capacity to produce up to 1 billion doses of the COVID-19 vaccine annually.

Medicago is the only company with plant-based manufacturing technology that has completed Phase III clinical trials (with its quadrivalent VLP influenza vaccine candidate) and pandemic Phase II clinical trials (with its H1N1 pandemic vaccine candidate). The company’s first New Drug Submission for its seasonal recombinant quadrivalent VLP vaccine for active immunization against influenza in adults (18-64 years), is currently under review by Health Canada following the completion of a robust safety and efficacy clinical program in over 25,000 subjects.

In addition to its clinical development capabilities, Medicago has also demonstrated its capacity to produce a large amount of vaccines in a short period of time, with the production in 2012 of 10 million doses of monovalent pandemic influenza H1N1 vaccines in one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense.

Medicago’s plant-based platform

The company uses a proprietary plant-based technology to develop vaccines and protein-based therapeutics. Unlike traditional vaccination development, Medicago does not use animal products or live viruses to create its products. Instead, it uses Virus-Like Particles (VLPs) that mimic the shape and dimensions of a virus, which allows the body to recognize them and create an immune response in a non-infectious way. Clinical trial data suggest that VLPs have a multi-modal mechanism of action that is different from that of inactivated vaccines, activating both arms of the immune system – antibody and cell-mediated responses.

Medicago’s proprietary technology is rapid, versatile, and scalable. As soon as the genetic sequence of a virus is made available, Medicago can develop a clinical-grade vaccine candidate in only a few weeks. Its recombinant technology allows the production of a vaccine that precisely matches the circulating strains, such as in the case of seasonal influenza. The technology is easily scalable, allowing the company to increase volume of production by simply increasing the number of plants it uses.

Facilities

Medicago is headquartered in Quebec City, Canada, and plans to produce COVID-19 vaccines in its manufacturing facility in Durham, North Carolina (USA) and in its Quebec pilot plant. A new state-of-the-art manufacturing plant is under construction in Quebec City, and is planned to have the capacity to deliver up to 1 billion COVID-19 vaccines annually.

About Medicago

Medicago is a biopharmaceutical company headquartered in Quebec City with productions sites in Quebec, Canada and Durham, North Carolina, USA. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide.

For more information: www.medicago.com

Contact information

Media contact (English)
Alissa Von Bargen
+1-647-234-5975
Alissa.VonBargen@gcicanada.com

Media contact (French)
Marie-Pier Côté
+ 1-418-999-4847
mpcote@tactconseil.ca

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

On the Occasion of UN World Cities Day, Urban 20 (U20) Engagement Group of the G20, Announces the Creation of a “Global Urban Resilience Fund” in Response to COVID-1930.10.2020 11:05:00 CETPress release

The Urban 20 (U20), a G20 Engagement Group, today announced that it is working to create a Global Urban Resilience Fund, the first fund of its type developed by cities, for cities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201030005112/en/ U20 Chair H.E. Fahd Al-Rasheed at the U20 Mayors Summit (Photo: AETOSWire) Speaking about the announcement U20 Chair, H.E. Fahd Al-Rasheed, President of the Royal Commission for Riyadh City, noted; “We have the opportunity right now to learn from the impact of COVID-19, to study how to build cities which are more resilient and agile. The cities of the U20 have taken the lead to develop a fund for city action to combat the pandemic and mitigate future urban shocks. The goal of the fund is to accelerate the transmission of new learning and ideas for a more secure future for all urban residents.” The Fund comes as a response to the findings of the U20 Special Working Group (SWG) on COVID

CGTN: Challenges, Goals and Proposals From Communique of China's Ruling Party Plenum30.10.2020 04:13:00 CETPress release

The 19th Central Committee of the Communist Party of China (CPC) concluded its fifth plenary session in Beijing on Thursday with the release of a communique. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029006395/en/ The 14th Five-Year Plan (FYP) (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035 are the key topics of the communique. Here is a look at all the highlights from the communique of the meeting. Read the original article: here. Decisive success made in building a moderately prosperous society in all respects This year is the final year of China's 13th FYP period (2016-2020) and the communique highlighted that the implementation of the 13th FYP has been smooth. By adhering to the new development concept and unswervingly advancing reform and opening-up, great achievements have been made since the fourth plenary session, the communique said. During the pas

HKTDC Autumn Sourcing Week | ONLINE Opens in Nov30.10.2020 02:11:00 CETPress release

Hong Kong, while the COVID-19 outbreak continues to hamper global business activities, online sourcing has become the ultimate solution that makes trade transactions possible. Riding on the success of the debut Summer Sourcing Weeks | Go ONLINE, the HKTDC is organising its next online exhibition from 16-27 November, Autumn Sourcing Week | ONLINE (ASWO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029006379/en/ Autumn Sourcing Week | ONLINE (ASWO) (Graphic: HKTDC) Benjamin Chau, HKTDC Deputy Executive Director, said: “The uncertainties brought by the COVID-19 pandemic have led more small and medium-sized enterprises (SMEs) to focus on online promotions and operations, which has quickly become the ‘new normal’ for conducting business. Given that the pandemic has prevented buyers and exhibitors from meeting in person, the HKTDC has introduced online business matching to enable networking and deal-making.” Under the theme

Ergomotion Announces Opening of First Manufacturing Facility in North America29.10.2020 22:28:00 CETPress release

Ergomotion, part of the Keeson Technology Group and the largest manufacturer of adjustable bases worldwide, will open a 250,000 square foot manufacturing facility in Ciudad Juárez, Chihuahua, the company’s first assembly plant in North America. The expansion was fueled by the decision to increase product capabilities, oversee manufacturing functions, and ultimately to stay closer to Ergomotion’s customer base in the United States. “We see a prime opportunity with the North America expansion to enhance the customer service experience in the U.S.,” says Johnny Griggs, Chief Operating Officer at Ergomotion. “Our goal is to provide our partners with world class manufacturing and supply chain and to help grow and strengthen their business. We’re excited to partner with Ciudad Juárez to expand our manufacturing capabilities and make this project viable and successful.” Ergomotion is making a significant investment that will allow for the creation of 400 jobs, within the local economy. The Ju

IDEMIA Launches Converged Card to Enable Financial Inclusion with Identity and Payment Card Solution29.10.2020 17:45:00 CETPress release

IDEMIA, a global leader in identity and security solutions and the number one provider of driver’s licenses in the U.S., today announced the development of a Converged Card solution in partnership with Mastercard, allowing cardholders to safely and securely shop for everyday essentials. The solution will help bring more people into the formal economy in the U.S. who currently have limited or no access to financial services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005916/en/ IDEMIA Launches Converged Card to Enable Financial Inclusion with Identity and Payment Card Solution (Photo: Business Wire) Converged Card1 is a state-issued driver’s license or identification with a payment credential. This card or digital application will support state-subsidized programs, including unemployment benefits, housing and utility assistance, and tax refunds, allowing the government to automatically reach people that need funding

Airship Named a Leader in the 2020 Gartner Magic Quadrant for Mobile Marketing Platforms29.10.2020 16:34:00 CETPress release

Customer engagement companyAirship today announced that it has been named a Leader by Gartner, Inc. in its 2020 Magic Quadrant for Mobile Marketing Platforms.1 Among 13 vendors evaluated, Airship was positioned highest in its ability to execute and furthest to the right for its completeness of vision for the second consecutive year. A complimentary copy of the report is available from Airship. “Airship’s long held global leadership in customer engagement is experiencing dramatic acceleration, as new mobile-first capabilities like Airship Journeys make it much simpler and more effective to grow customer lifetime value in the omnichannel era. I believe Airship’s latest innovations, as well as expansions to experimentation and commerce, are already recognized as major beneficial differentiators in comprehensive evaluations like Gartner’s Magic Quadrant and Critical Capabilities reports,” said Brett Caine, CEO and president, Airship. “As mobile becomes increasingly vital for brands and the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom